Glioblastoma, the most common and aggressive type of cancerous brain tumor in adults, poses significant treatment challenges despite available options such as surgery, radiation and chemotherapy.
Patients diagnosed with glioblastoma typically have a life expectancy of only 12 to 18 months after diagnosis.
The team developed a new nanoformulation, called Immunosomes, that combines a CD40 agonist antibody with the small molecule inhibitor RRX-001. This innovative approach, published in the journal Biomaterials, aims to improve the effectiveness of brain tumor treatment, potentially offering new hope for improving outcomes in patients with glioblastoma.
In this study, glioblastoma-bearing mice treated with immunosomes showed complete tumor eradication and remained tumor-free for at least three months. Additionally, the treatment generated a strong host immune response to fight brain cancer. After three months, the team again challenged the long-term surviving mice by implanting glioblastoma cells.
Surprisingly, mice pretreated with immunosomes showed almost no tumor growth, revealing that immunosomes could generate long-lasting immune memory that can prevent future tumor recurrence without additional treatment.
In addition to producing long-lasting protection against glioblastoma, immunosome treatment may reduce the toxicity associated with the CD40 agonistic antibody, which otherwise presents a major challenge to clinicians worldwide.
"We are very motivated by these results and are excited to translate them into human clinical trials with a broader range of glioblastoma patients," said Dr. Jayanta Bhattacharyya, associate professor at the Center for Biomedical Engineering at IIT Delhi.
Patients diagnosed with glioblastoma typically have a life expectancy of only 12 to 18 months after diagnosis.
The team developed a new nanoformulation, called Immunosomes, that combines a CD40 agonist antibody with the small molecule inhibitor RRX-001. This innovative approach, published in the journal Biomaterials, aims to improve the effectiveness of brain tumor treatment, potentially offering new hope for improving outcomes in patients with glioblastoma.
In this study, glioblastoma-bearing mice treated with immunosomes showed complete tumor eradication and remained tumor-free for at least three months. Additionally, the treatment generated a strong host immune response to fight brain cancer. After three months, the team again challenged the long-term surviving mice by implanting glioblastoma cells.
Surprisingly, mice pretreated with immunosomes showed almost no tumor growth, revealing that immunosomes could generate long-lasting immune memory that can prevent future tumor recurrence without additional treatment.
In addition to producing long-lasting protection against glioblastoma, immunosome treatment may reduce the toxicity associated with the CD40 agonistic antibody, which otherwise presents a major challenge to clinicians worldwide.
"We are very motivated by these results and are excited to translate them into human clinical trials with a broader range of glioblastoma patients," said Dr. Jayanta Bhattacharyya, associate professor at the Center for Biomedical Engineering at IIT Delhi.
